(Q34753158)

4 August 2017

title

Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? (English)

1 reference

4 August 2017

0 references

Steven L Teitelbaum

1

0 references

author name string

Margaret P Seton

series ordinal

2

1 reference

4 August 2017

Kenneth G Saag

series ordinal

3

1 reference

4 August 2017

publication date

1 February 2011

1 reference

4 August 2017

published in

Arthritis & Rheumatology

1 reference

4 August 2017

volume

63

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

325-328

1 reference

Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Bisphosphonates: mechanism of action and role in clinical practice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Glucocorticoid-induced osteoporosis in children: impact of the underlying disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Glucocorticoids suppress bone formation via the osteoclast

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Bone quality--the material and structural basis of bone strength and fragility

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Glucocorticoid-induced osteoporosis: an update

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Severely suppressed bone turnover: a potential complication of alendronate therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Bone histomorphometry in glucocorticoid-induced osteoporosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069536

Ten years' experience with alendronate for osteoporosis in postmenopausal women

7 July 2018

1 reference

Effects of low-dose prednisone on bone metabolism

21 January 2018

1 reference

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

21 January 2018

1 reference

Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

21 January 2018

1 reference

Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.

21 January 2018

1 reference

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.

21 January 2018

1 reference

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis

21 January 2018

1 reference

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

21 January 2018

1 reference

21 January 2018

1 reference

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

21 January 2018

1 reference

12 December 2020

Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography

1 reference

12 December 2020

The course of biochemical parameters of bone turnover during treatment with corticosteroids

1 reference

12 December 2020

Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis

1 reference

12 December 2020

Bone turnover markers and bone density across the menopausal transition

1 reference

12 December 2020

Pathogenesis and treatment of glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

12 December 2020

Glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Identifiers

DOI

10.1002/ART.30135

1 reference

4 August 2017

1 reference

4 August 2017

1 reference